However, we found a significant reduction of both SCF and TPO following the treatment, on day 93 (Figure 8c and d), suggesting that immunosuppression and IgG cleavage can affect the production of HGFs during anti-GBM disease. The gene discussed is KITLG; the disease is glioblastoma.